Press Releases March 29, 2026 08:00 PM

Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

Teladoc Health strengthens leadership with appointment of healthcare industry veteran Susan Salka to board

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TDOC

Teladoc Health has appointed Susan Salka, former President and CEO of AMN Healthcare Services, to its board of directors. Salka brings extensive experience in healthcare leadership and governance, expected to support Teladoc's growth and transformation in virtual care. She will join audit and compensation committees and succeeds retiring board members, contributing to strategic oversight in an evolving healthcare sector.

Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors
TDOC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Susan Salka, a seasoned healthcare executive with 33 years at AMN Healthcare, joins Teladoc's board, enhancing leadership expertise.
  • Her experience includes managing healthcare workforce technology and multiple acquisitions driving significant revenue growth.
  • This leadership addition supports Teladoc's mission to transform virtual care and improve health outcomes at scale.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board’s audit and compensation committees.

“Susan brings a powerful combination of healthcare leadership and governance experience to the Board,” said Kenneth H. Paulus, non‑executive Chairman of the Teladoc Health board. “We will benefit from her insights on care delivery transformation as the company drives health outcomes at scale and creates durable value.”

During her 33-year tenure at AMN Healthcare, Ms. Salka was one of the driving forces behind the company's strategic and operational success. AMN pioneered the evolution of workforce solutions and made 26 acquisitions to meet the changing needs of clients, transforming the company and growing revenue to over $5 billion.

Ms. Salka currently serves on the board of Parexel International and previously served on the boards of McKesson Corporation, Beckman Coulter and Playtex Products. She holds an MBA in Finance from San Diego State University and a BA in Accounting and Economics from Chadron State College.

“Integrated, outcomes focused care is central to creating lasting value in healthcare,” said Salka. “Teladoc Health is an innovative leader and I look forward to contributing strategic and operational perspectives on the company’s next phase of growth.”

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Investors:
Michael Minchak
[email protected]
617-444-9612

Media:
Lou Serio
[email protected]
202-569-9715


Risks

  • Integration challenges in leveraging Susan Salka's experience within Teladoc's existing board dynamics and corporate strategy.
  • Continued competitive pressures in virtual healthcare requiring effective governance and strategic agility.
  • Dependence on healthcare policies and reimbursement landscape affecting virtual care adoption rates.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026